All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2017-01-10T14:10:40.000Z

FDA Halts Phase I Trials of Vadastuximab Talirine in AML

Jan 10, 2017
Share:

Bookmark this article

Clinical trials of the experimental drug vadastuximab talirine (SGN-CD33A; a CD33-directed antibody drug conjugate) for patients with Acute Myeloid Leukemia (AML) have been placed on hold by the U.S. Food and Drug Administration (FDA). This novel agent had been previously awarded orphan drug status by the FDA and the European Medicines Agency for the treatment of AML.

The trials have been halted after four patients who were treated with vadastuximab talirine along with Allogeneic Hematopoietic Cell Transplant (AHCT), either prior to or following treatment, died. All four of these patients had veno-occlusive disease at the time of death; two additional trial participants also had hepatotoxicity. The possible link between risk of hepatotoxicity and treatment with vadastuximab talirine is being evaluated. In addition, identification of the appropriate protocol revisions are being reviewed.

Consequently, Seattle Genetics, the drug’s manufacturers, have halted any further enrolment of their phase I/II trial clinical trials of vadastuximab talirine in pre- and post-AHCT patients. In addition, a study investigating the combination of vadastuximab talirine with hypomethylating agents in older patients with AML has also been put on hold as well as another study investigating combining the 7+3 chemotherapy with vadastuximab talirine in younger, newly diagnosed AML patients.

Nonetheless, the phase III CASCADE trial in older AML patients and a phase I/II trial in Myelodysplastic Syndrome is still proceeding with enrolment.

  1. OncLive. FDA Halts Several Trials of Vadastuximab Talirine in AML.http://www.onclive.com/web-exclusives/fda-halts-several-trials-of-vadastuximab-talirine-in-aml. 2016 December 27. [Accessed 2017 January 9].

Your opinion matters

Do you intend to implement next generation sequencing for measurable residual disease monitoring in AML patients?
0 votes - 6 days left ...

Newsletter

Subscribe to get the best content related to AML delivered to your inbox